jcp conference-coverage

Conference Coverage

Conference Coverage

Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer

03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...

At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...

At the SGO 2024 Annual Meeting,...

03/18/2024

Oncology

News

AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity

03/18/2024

Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.

Artificial intelligence machine...

03/18/2024

Journal of Clinical Pathways

Conference Coverage

Addition of Induction Chemotherapy to Chemoradiation Improves Survival Outcomes Among Patients with Locally Advanced Cervical Cancer

03/17/2024

Allison Casey

According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.

According to a phase 3 trial,...

03/17/2024

Oncology

Conference Coverage

Sentinel Lymph Node Biopsy Without Systematic Pelvic Lymphadenectomy is Safe, Effective for Patients With Early-Stage Cervical Cancer

03/17/2024

Featuring David Cibula, MD, PhD

Featuring David Cibula, MD, PhD ...

At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...

At the SGO 2024 Annual Meeting,...

03/17/2024

Oncology

Conference Coverage

Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer

03/16/2024

Stephanie Holland

According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...

According to results from the...

03/16/2024

Oncology

Conference Coverage

Atezolizumab Plus Bevacizumab and Chemotherapy As New First-Line Treatment Option for Recurrent or Metastatic Cervical Cancer

03/16/2024

Allison Casey

According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...

According to results from a...

03/16/2024

Oncology

Conference Coverage

Tisotumab Vedotin Improves Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer

03/16/2024

Amber Denham

Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...

Tisotumab vedotin demonstrated a...

03/16/2024

Oncology

Jennifer Amengual, MD, Columbia University

Conference Coverage

Exploring Treatment Strategies for Elderly Patients With Aggressive Lymphoma Ineligible for CAR T-Cell Therapy

03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...

At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.

At the Lymphoma, Leukemia &...

03/11/2024

Lymphoma, Leukemia & Myeloma Network

Videos

The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study

03/04/2024

Featuring Amanda Nizam, MD

Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.

Amanda Nizam, MD, discusses the...

03/04/2024

Journal of Clinical Pathways

Videos

Technology for Biosimilar Substitution to Enhance Practice Efficiency and Financial Health

03/01/2024

Featuring Stephen V. Speicher, MD, MS

Featuring Stephen V. Speicher, MD, MS...

Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”

Stephen V. Speicher, MD, MS,...

03/01/2024

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products